Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

BX471 hydrochloride

BX471 hydrochloride
Contact us for more batch information

BX471 hydrochloride

Catalog No. T14845Cas No. 288262-96-4
BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide CCR1 antagonist (Ki: 1 nM for human CCR1). It shows 250-fold selectivity for CCR1 over CCR2, CCR5, and CXCR4.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
TargetMol
Product information is being updated, if you want to purchase, please click the bulk custom button.
Bulk & Custom
Questions
View More

Product Introduction

Bioactivity
Description
BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide CCR1 antagonist (Ki: 1 nM for human CCR1). It shows 250-fold selectivity for CCR1 over CCR2, CCR5, and CXCR4.
In vitro
BX471 is a potent functional antagonist based on its ability to inhibit a number of CCR1-mediated effects including Ca2+ mobilization, increase in extracellular acidification rate, CD11b expression, and leukocyte migration and it is also able to displace 125I-MIP-1α/CCL3 binding to mouse CCR1 in a concentration-dependent manner (Ki: 215 nM). BX471 demonstrates a greater than 10,000-fold selectivity for CCR1 compared with 28 G-protein-coupled receptors [1]. BX471 also inhibits the RANTES-mediated adhesion of T lymphocytes to activated endothelium [4]. BX471 (0.1-10 μM) shows dose-dependent inhibition of RANTES-mediated and shear-resistant adhesion on IL-1β-activated microvascular endothelium in shear flow in isolated blood monocytes. Increasing concentrations of BX471 inhibits the Ca2+ transients induced by MIP-1α/CCL3 in both human and mouse CCR1 (IC50s: 5.8 nM and 198 nM) [2].
In vivo
BX471 demonstrates a marginally significant impact on the quantity of CCR5-positive CD8 cells in peripheral blood and notably decreases FSP1-positive cells in UUO kidneys by 65% compared to the vehicle control, highlighting its efficacy [2]. Administered orally or intravenously at 4 mg/kg, it shows a bioavailability of 60% in dogs, indicating good oral activity. Moreover, BX471 significantly mitigates symptoms in a rat model of experimental allergic encephalomyelitis, which is a model for multiple sclerosis [1], illustrating its potential therapeutic benefits. At a dosage of 20 mg/kg subcutaneously, it reaches a peak plasma concentration of 9 μM within 30 minutes, but this level sharply falls to roughly 0.4 μM after 2 hours, and declines further to 0.1 μM or less from 4 to 8 hours post-administration. In mice, a 10-day treatment with BX471 at 20 mg/kg results in a 55% reduction in interstitial CD45 positive leukocytes, demonstrating its anti-inflammatory properties. Additionally, pretreatment with BX471 effectively reduces macrophage and neutrophil build-up in the kidney following ischemia-reperfusion injury [3], showcasing its potential in protecting renal function from injury-induced inflammation.
AliasZK-811752 hydrochloride
Chemical Properties
Molecular Weight471.35
FormulaC21H25Cl2FN4O3
Cas No.288262-96-4
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 150 mg/mL (318.23 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.1216 mL10.6078 mL21.2157 mL106.0783 mL
5 mM0.4243 mL2.1216 mL4.2431 mL21.2157 mL
10 mM0.2122 mL1.0608 mL2.1216 mL10.6078 mL
20 mM0.1061 mL0.5304 mL1.0608 mL5.3039 mL
50 mM0.0424 mL0.2122 mL0.4243 mL2.1216 mL
100 mM0.0212 mL0.1061 mL0.2122 mL1.0608 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords